Irinotecan liposomal injection (Onivyde) granted Fast Track designation in the US for the treatment of small cell lung cancer

Onivyde is being evaluated as monotherapy in a Phase III study in patients who have progressed on or after a first-line platinum-based regimen. It is currently licensed in the UK for the treatment of metastatic adenocarcinoma of the pancreas.

Source:

Biospace Inc.